Zobrazeno 1 - 10
of 1 218
pro vyhledávání: '"imatinib resistance"'
Publikováno v:
Xin yixue, Vol 55, Iss 9, Pp 751-756 (2024)
Circular RNAs （circRNA） are a class of multifunctional non-coding RNAs with a covalently ring structure， playing a variety of biological roles within cells. Chronic myelogenous leukemia （CML） is a myeloproliferative disorder originating fro
Externí odkaz:
https://doaj.org/article/ac2726e99ea448b5a0eba049ee9c82e7
Publikováno v:
Cell Communication and Signaling, Vol 22, Iss 1, Pp 1-21 (2024)
Abstract Gastrointestinal stromal tumor (GIST) is the most common sarcoma located in gastrointestinal tract and derived from the interstitial cell of Cajal (ICC) lineage. Both ICC and GIST cells highly rely on KIT signal pathway. Clinically, about 80
Externí odkaz:
https://doaj.org/article/18f95946ed9b4e968dddc7df9f1b07a8
Autor:
Jordi López-Gómez, Laura Villarreal, Marta Andrés, Inma Ponte, Blanca Xicoy, Lurdes Zamora, Marta Vilaseca, Alicia Roque
Publikováno v:
Biomolecules, Vol 14, Iss 10, p 1221 (2024)
Histone H1 is involved in the regulation of chromatin structure. Human somatic cells express up to seven subtypes. The variability in the proportions of somatic H1s (H1 complement) is one piece of evidence supporting their functional specificity. Alt
Externí odkaz:
https://doaj.org/article/94705b296dd040da83576081e473a100
Autor:
Seiichi Okabe, Akihiko Gotoh
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background Abelson (ABL) tyrosine kinase inhibitors (TKIs) are effective against chronic myeloid leukemia (CML); however, many patients develop resistance during ABL TKI therapy. Vitamin K2 (VK2) is a crucial fat-soluble vitamin used to acti
Externí odkaz:
https://doaj.org/article/9d444521026f451ba0a70499d722cdbc
Autor:
Rui Su, Chuting Li, Xiuyuan Wang, Zhendong Li, Ziqi Wen, Zhao Yin, Guiping Huang, Yanjun Liu, Juhua Yang, Haiyan Hu, Hong Nie, Keda Zhang, Jia Fei
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 32, Iss , Pp 729-742 (2023)
A large proportion of patients with chronic myeloid leukemia (CML; 20%–50%) develop resistance to imatinib in a BCR-ABL1-independent manner. Therefore, new therapeutic strategies for use in this subset of imatinib-resistant CML patients are urgentl
Externí odkaz:
https://doaj.org/article/d06e377d9f1e4c018fd25423ef6dd82e
Autor:
Ashraf K. El-Damasy, Hyun Ji Kim, Jung Woo Park, Yunju Nam, Wooyoung Hur, Eun-Kyoung Bang, Gyochang Keum
Publikováno v:
Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 38, Iss 1 (2023)
BCR-ABL inhibition is an effective therapeutic approach for the treatment of chronic myeloid leukaemia (CML). Herein, we report the discovery of AKE-72 (5), a diarylamide 3-aminoindazole, as a potent pan-BCR-ABL inhibitor, including the imatinib-resi
Externí odkaz:
https://doaj.org/article/b282f6bb9b90428e8aa1d7677a46c18c
Autor:
Ashraf K. El-Damasy, Heewon Jin, Jung Woo Park, Hyun Ji Kim, Hanan Khojah, Seon Hee Seo, Ju-Hyeon Lee, Eun-Kyoung Bang, Gyochang Keum
Publikováno v:
Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 38, Iss 1 (2023)
The design of kinase inhibitors targeting the oncogenic kinase BCR-ABL constitutes a promising paradigm for treating chronic myeloid leukaemia (CML). Nevertheless, the efficacy of imatinib, the first FDA-approved targeted therapy for CML, is curbed b
Externí odkaz:
https://doaj.org/article/f79db7a7810b42be86ef54f6e1581a0e
Autor:
S. I. Kutzev, S. V. Mordanov
Publikováno v:
Онкогематология, Vol 0, Iss 3, Pp 57-60 (2022)
The treatment of Ph-positive chronic myeloid leukemia (CML) has achieved significant progress with the tyrosine kinase inhibitor (TKI) imatinib. Complete cytogenetic remission is a standard for patients treated in chronic phase. Nevertheless, primary
Externí odkaz:
https://doaj.org/article/9604ce74dacb408a8ca5cf7c4b8621b5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a BCR-ABL fusion gene. Imatinib has significantly improved the treatment of CML as a first-generation tyrosine kinase inhibitor (TKIs). The T315I mutant form of BCR-ABL is the
Externí odkaz:
https://doaj.org/article/8cda950c119841debfe2754f39f1b3ea